Xeris Biopharma Holdings Inc (0A8E.L)

Name: Xeris Biopharma Holdings Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$85.8M

Net Income

$11.1M

Operating Margin

19.5%

Free Cash Flow

$27.9M

Debt / Assets

96.4%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Xeris Biopharma Holdings Inc (0A8E.L).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Revenue	85,807,000	74,380,000	71,539,000	60,119,000
Cost of Revenue	19,079,000	10,996,000	14,609,000	8,728,000
Gross Profit	66,728,000	63,384,000	56,930,000	51,391,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	47,502,000	46,459,000	44,393,000	44,018,000
Operating Expenses	49,955,000	56,653,000	52,448,000	54,481,000
Operating Income	16,773,000	6,731,000	4,482,000	-3,090,000
Interest Expense	7,153,000	7,268,000	7,358,000	7,305,000
Income Before Tax	11,081,000	621,000	-1,928,000	-9,220,000
Income Tax Expense	0	0	0	0
Net Income	11,081,000	621,000	-1,928,000	-9,220,000
Per Share
EPS	0.07	0.00	-0.01	-0.06
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Xeris Biopharma Holdings Inc (0A8E.L).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	291,845,000	203,070,000	163,914,000	110,248,000
Cost of Revenue	53,412,000	36,832,000	28,645,000	22,634,000
Gross Profit	238,433,000	166,238,000	135,269,000	87,614,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	182,372,000	163,481,000	146,095,000	137,745,000
Operating Expenses	213,537,000	199,884,000	179,279,000	169,554,000
Operating Income	24,896,000	-33,646,000	-44,010,000	-81,940,000
Interest Expense	29,084,000	33,175,000	26,609,000	15,325,000
Income Before Tax	554,000	-57,104,000	-63,504,000	-96,084,000
Income Tax Expense	0	-2,268,000	-1,249,000	-1,424,000
Net Income	554,000	-54,836,000	-62,255,000	-94,660,000
Per Share
EPS	0.00	-0.37	-0.45	-0.70
EPS Diluted	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Xeris Biopharma Holdings Inc (0A8E.L).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	111,042,000	71,621,000	67,449,000	121,966,000
Short Term Investments	0	0	5,002,000	0
Net Receivables	51,050,000	40,415,000	39,197,000	30,830,000
Inventory	68,673,000	48,175,000	38,838,000	24,735,000
Total Current Assets	240,313,000	167,662,000	156,264,000	186,818,000
Property Plant Equipment	27,057,000	28,211,000	29,175,000	28,375,000
Goodwill and Intangibles	110,937,000	121,780,000	132,623,000	124,599,000
Total Assets	383,527,000	323,060,000	322,602,000	344,522,000
Liabilities
Account Payables	3,076,000	2,290,000	11,565,000	4,606,000
Short Term Debt	6,232,000	21,182,000	3,495,000	1,580,000
Total Current Liabilities	109,574,000	100,443,000	95,193,000	73,621,000
Long Term Debt	31,531,000	250,265,000	225,696,000	196,477,000
Total Liabilities	369,838,000	352,675,000	329,384,000	299,335,000
Shareholders Equity
Retained Earnings	-671,307,000	-671,861,000	-617,025,000	-554,770,000
Total Shareholders Equity	13,689,000	-29,615,000	-6,782,000	45,187,000

Balance sheet annual history for Xeris Biopharma Holdings Inc (0A8E.L).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	111,042,000	71,621,000	67,449,000	121,966,000
Short Term Investments	0	0	5,002,000	0
Net Receivables	51,050,000	40,415,000	39,197,000	30,830,000
Inventory	68,673,000	48,175,000	38,838,000	24,735,000
Total Current Assets	240,313,000	167,662,000	156,264,000	186,818,000
Property Plant Equipment	27,057,000	28,211,000	29,175,000	28,375,000
Goodwill and Intangibles	110,937,000	121,780,000	132,623,000	124,599,000
Total Assets	383,527,000	323,060,000	322,602,000	344,522,000
Liabilities
Account Payables	3,076,000	2,290,000	11,565,000	4,606,000
Short Term Debt	6,232,000	21,182,000	3,495,000	1,580,000
Total Current Liabilities	109,574,000	100,443,000	95,193,000	73,621,000
Long Term Debt	31,531,000	250,265,000	225,696,000	196,477,000
Total Liabilities	369,838,000	352,675,000	329,384,000	299,335,000
Shareholders Equity
Retained Earnings	-671,307,000	-671,861,000	-617,025,000	-554,770,000
Total Shareholders Equity	13,689,000	-29,615,000	-6,782,000	45,187,000

Cash flow quarterly history for Xeris Biopharma Holdings Inc (0A8E.L).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	554,000	-54,836,000	-62,255,000	-94,660,000
Depreciation & Amortization	12,156,000	12,625,000	13,160,000	12,668,000
Stock Based Compensation	22,366,000	18,363,000	10,716,000	12,160,000
Change in Working Capital	-10,360,000	-8,820,000	-6,294,000	-35,150,000
Operating Cash Flow	28,626,000	-36,981,000	-47,023,000	-102,891,000
Investing Activities
Capital Expenditure	-696,000	-868,000	-2,263,000	-524,000
Investments	-696,000	-868,000	-2,263,000	-524,000
Investing Cash Flow	-696,000	4,883,000	-6,004,000	34,461,000
Financing Activities
Debt Repayment	9,167,000	38,169,000	0	102,718,000
Common Stock Issued/Repurchased	2,222,000	-3,734,000	-1,009,000	29,532,000
Dividends Paid	0	0	0	0
Financing Cash Flow	11,389,000	36,168,000	-1,613,000	127,473,000
Summary
Free Cash Flow	27,930,000	-37,849,000	-49,286,000	-103,415,000
Net Change in Cash	39,319,000	4,070,000	-54,640,000	59,043,000

Cash flow annual history for Xeris Biopharma Holdings Inc (0A8E.L).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	554,000	-54,836,000	-62,255,000	-94,660,000
Depreciation & Amortization	12,156,000	12,625,000	13,160,000	12,668,000
Stock Based Compensation	22,366,000	18,363,000	10,716,000	12,160,000
Change in Working Capital	-10,360,000	-8,820,000	-6,294,000	-35,150,000
Operating Cash Flow	28,626,000	-36,981,000	-47,023,000	-102,891,000
Investing Activities
Capital Expenditure	-696,000	-868,000	-2,263,000	-524,000
Investments	-696,000	-868,000	-2,263,000	-524,000
Investing Cash Flow	-696,000	4,883,000	-6,004,000	34,461,000
Financing Activities
Debt Repayment	9,167,000	38,169,000	0	102,718,000
Common Stock Issued/Repurchased	2,222,000	-3,734,000	-1,009,000	29,532,000
Dividends Paid	0	0	0	0
Financing Cash Flow	11,389,000	36,168,000	-1,613,000	127,473,000
Summary
Free Cash Flow	27,930,000	-37,849,000	-49,286,000	-103,415,000
Net Change in Cash	39,319,000	4,070,000	-54,640,000	59,043,000